Scarica l'app Stockscreener
3.63
4.31%
0.15
Dopo l'orario di chiusura:
3.56
-0.07
-1.93%
Precedente Chiudi:
$3.48
Aprire:
$3.54
Volume 24 ore:
18,986
Relative Volume:
0.03
Capitalizzazione di mercato:
$4.88M
Reddito:
-
Utile/perdita netta:
$-11.00M
Rapporto P/E:
-9.1759
EPS:
-0.3956
Flusso di cassa netto:
$-11.99M
1 W Prestazione:
-1.89%
1M Prestazione:
-37.95%
6M Prestazione:
-70.00%
1 anno Prestazione:
-96.42%
Intervallo 1D:
$3.4505
$3.80
Intervallo di 1 settimana:
$3.4505
$3.82
Portata 52W:
$3.42
$141.50
Liminatus Pharma Inc Stock (LIMN) Company Profile
Nome
Liminatus Pharma Inc
Settore
Industria
Telefono
213-273-5453
Indirizzo
12611 HIDDENCREEK WAY, CERRITOS
Compare LIMN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
3.63 | 4.67M | 0 | -11.00M | -11.99M | -0.3956 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Liminatus Pharma Inc Borsa (LIMN) Ultime notizie
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Price to sales forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma selects Synex to advance CAR-T trial - Clinical Trials Arena
Liminatus engages Synex for IBC101 CAR-T clinical development - Investing.com
Liminatus Pharma Engages Synex Consulting to Support Clinical Development of IBC101 CAR-T Therapy in South Korea - quiverquant.com
Liminatus engages Synex for IBC101 CAR-T clinical development By Investing.com - Investing.com UK
Korea’s Ministry of Food and Drug Safety authorizes Liminatus study - Stock Titan
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy - Yahoo Finance
Nasdaq Orders Immediate Suspension of Flash Sports & Media Stock - Minichart
Press Releases about Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) - FinancialContent
17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026. - marketscreener.com
Liminatus Pharma to implement 1-for-50 reverse stock split - Investing.com
Liminatus Pharma Enacts Reverse Split to Maintain Listing - TipRanks
Liminatus Pharma announces 1-for-50 reverse stock split - TipRanks
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com India
Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Liminatus Pharma (LIMN) Stock Analysis Report | Financials & Insights - Benzinga France
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusScalping Stock Signals - vinanet.vn
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportLow Vol ETF - vinanet.vn
Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats - Stock Titan
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update - TipRanks
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market - Investing.com
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Bid Price Compliance - Quiver Quantitative
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance ... - Herald and News
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance With Minimum Bid Price Requirement - Moomoo
$Liminatus Pharma (LIMN.US)$ - moomoo.com
Liminatus Pharma Warrants (LIMNW) Jump 34% to $0.07 as Traders Eye Key Inflection PointFear Greed Extreme - vinanet.vn
Liminatus Pharma (LIMN) Edges Higher as Micro-Cap Biotech Holds Key $0.10 Support LevelTriple Bottom - dars.gov.et
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan - The Globe and Mail
Liminatus Pharma Warrants (LIMNW) Remain Flat at $0.06 as Key Levels ConvergePut Dominated - dars.gov.et
Liminatus Pharma, Inc. Primary Exchange Listing has Changed to Nasdaq Capital Market from Nasdaq Global Market - marketscreener.com
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMN - TradingView
Liminatus Pharma Reports Improved Nasdaq Listing Compliance Status - TipRanks
Liminatus Pharma (NASDAQ: LIMN) cites $2.5M equity in Nasdaq compliance review - Stock Titan
LIMN|Liminatus Pharma Ord Shs Class A|Price:4.410|Chg%:-0.200 - TradingKey
LIMN|Liminatus Pharma Ord Shs Class A|Price:0.119|Chg%:+0.002 - TradingKey
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMNW - TradingView
Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split - The Globe and Mail
Liminatus Pharma, Inc. Revenue Breakdown – BOATS:LIMN - TradingView
Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis - Kalkine
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
Liminatus Pharma Inc Azioni (LIMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):